Market Overview

UPDATE: Goldman Sachs Initiates Align Technology at Neutral; Near-Term Visibility Lacking

Related ALGN
5 Health Care Stocks Hurting From The Affordable Care Act
Align Technology Surges 5% Amid Credit Suisse Upgrade

Goldman Sachs initiated coverage on Align Technology (NASDAQ: ALGN) with a Neutral rating and a $28 price target.

Goldman Sachs noted, "Our proprietary survey of 100 US GPs/Orthodontists supports our long-term view that Align is well positioned to leverage its dominant market share in a significantly underpenetrated space, where we model a 2012-2015 case CAGR of 15%. That said, Align's 3Q miss (first sales miss in five years) and negative 4Q preannouncement, which came with management departures, have introduced near-term uncertainty. From here, we would need to see a reacceleration in growth before we become more positive."

Align Technology closed at $26.20 on Monday.

Latest Ratings for ALGN

DateFirmActionFromTo
Oct 2014Goldman SachsUpgradesNeutralBuy
Oct 2014Credit SuisseUpgradesNeutralOutperform
Jul 2014JefferiesMaintainsHold

View More Analyst Ratings for ALGN
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Initiation Pre-Market Outlook Analyst Ratings

 

Related Articles (ALGN)

Around the Web, We're Loving...

Get Benzinga's Newsletters